Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma

Trial Profile

Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 28 Sep 2017 Planned End Date changed from 1 Feb 2019 to 1 Aug 2020.
    • 09 Oct 2015 Planned end date changed from 1 Feb 2018 to 1 Feb 2019, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top